CN |CAS  
 
  Home | Links | Site map
 
Home About Us News Organization Research Faculty Publication Education&Training Contact
  Research
Location: Home > Research
 
 
Research
Target
Discovery
Development
Translation
 
The first-in-class anti-HBV drug, isothiafludine, approved for clinical trial
Update time: 2012-04-16
Close
Text Size: A A A
Print
Hepatitis B virus (HBV) infection is a serious global health problem. Approximately 2 billion people have been infected worldwide and 400 million suffering from chronic HBV infection. The current standard therapies, mainly interferon and nucleoside analogues, are limited by their efficacy and viral resistance, therefore the demand for new anti-HBV drug is still high.
The research team led by Professors NAN Fajun  and  ZUO Jianping from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, has been identifying novel agents from natural product-based synthetic compound libraries for anti-HBV therapy following more than 7 years' endeavors. Through SAR studies and hit optimizations, the team has identified a novel non-nucleoside anti-HBV drug candidate, isothiafludine (known as NZ-4 or W28F). SIMM has filed the patent applications in 8 major countries and areas including China, US, Europe and Japan. On March 5th, 2012, the first-in-class anti-HBV drug, isothiafludine and its capsule, has been approved by State Food and Drug Administration (SFDA) for Phase I clinical trial.
With novel anti-HBV replication mechanism, isothiafludine has demonstrated potent anti-viral activity both in vivo and in vitro. In addition, isothiafludine has shown inhibition effect against the nucleoside resistant HBV virus which means that it could potentially provide new therapy to the nucleoside resistant patients. The clinical trial is carried out by Shanghai HaiHe Pharmaceutical Co., Ltd., founded jointly by SIMM and Shanghai Zhangjiang Science & Technology Venture Captical.
 
weimoban
About Us News Research Faculty Education&Trainning Organization Contact
Brief Introduction
History
Address from the Director
Directors
Administration
Research
Events
Int'l cooperation
Target
Discovery
Development
Translation
Academician
PI
Graduate Students
Post Graduate Students